Administration of the therapeutic copper-bis(thiosemicarbazonato) complex, Cu(gtsm), delivered bioavailable Cu to the brain of APP/PS1 AD model mice and improved amyloid and tau pathology, as well as indicators of cognitive function [145]. This evidence concerns the gene APP and Alzheimer disease.